This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...
Phase 2b (CBeyond 2) plan to be finalized in Q1; trial launch targeted for Q3 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback